Product Development

IP Development: StructuredIP™

Creating what’s next in healthcare

As a global leader in the healthcare and life science industry, Alira Health has a clear vision of what’s next in the patient care market.

We bring this expertise to our StructuredIP™ process to ensure that your IP is novel, inventive, broad, and innovative to make certain your portfolio has the most commercial value and is best aligned with your overall business strategy.

We also provide expert witnesses to support patent litigation for biologic products. Our CMC specialists often serve as expert witnesses for companies intending to protect or challenge IP on biologic products.

IP that improves outcomes

We employ the full breadth of our healthcare and life science skills to develop IP that solves problems, improves health, and is worthy of your investment. We are an industry-leader in IP for:
  • Pharmaceuticals and Life Sciences
    Our team of experts can help you innovate early stage biotech, RX, pharmaceuticals, and OTC products. With decades of experience, we understand the science behind the cause of disease
  • Medical Devices and Healthcare IT
    Our team of scientists and doctors know what caregivers and payers need to diagnose, monitor, manage, and treat disease

Why choose Alira Health?

As your partner, we can assist in new IP development as well as IP portfolio management and due diligence for investors and strategic partners. We’ll work closely with you on:

  • Development of new IP
  • Competition and competitive landscape evaluation
  • Patent writing and claim set analysis
  • Technical due diligence for investments and M&A
  • IP portfolio management

Related news

MedTech
News March 3, 2021
The 2021 MedTech Contract Manufacturing Report
Download our latest piece: The 2021 MedTech Contract Manufacturing Report. Learn how despite the ongoing pandemic, the Medical Device and CDMO industries are positioned to perform(...)
M&A
Publications February 28, 2021
What’s most important when selecting a firm for your next transaction?
Market Access MedTech
Multimedia February 26, 2021
Pricing in MedTech: Disentangling the Roles of Payers, DRGs, and Procurement
Join host Kenny Carberry, Associate Director of Clinical Development, Dan Legg, former Director of Clinical Sourcing at Guy’s & St Thomas at the St Thomas Hospital in London and CEO(...)
M&A
Publications February 24, 2021
What You Should Know Before Choosing a Healthcare Transaction Advisory Firm
What’s most important when selecting a firm for your next transaction? Global experience, staff profiles, technical expertise? To learn more download our latest TAD Infographic.
MedTech Pharma
Publications February 8, 2021
Infographic: 2021 Trends in Healthcare
It is no secret that the COVID-19 pandemic has presented new challenges for businesses, and virtual has become the ‘new normal’, including for transactions.
MedTech Pharma
News February 4, 2021
2020 Year in Review
With 2021 in full swing, we want to take a moment to reflect on last year’s achievements and congratulate the entire Alira Health Team for their hard work and dedication to healthcare(...)
Regulatory
News February 2, 2021
We Secured Breakthrough Device Designation from FDA on PEDRA Xauron Perfusion System
We are proud to announce the firm’s Regulatory practice has secured a Breakthrough Device Designation from FDA for the real-time tissue perfusion system, PEDRA Xauron Perfusion System.

Our locations around the globe

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.